Green tea-mediated inhibition of aberrant DNA hypermethylation in prostate cancer

Project: Research project

Description

DESCRIPTION (provided by applicant): A role for green tea in the prevention of human prostate cancer is supported by both epidemiological studies and laboratory investigations. Green tea extract (GTP) contains a number of bioactive polyphenolic compounds that account for its anti-carcinogenic properties. Previous studies have shown that oral infusion of GTP dramatically reduces tumor burden and metastasis in a spontaneous autochthonous transgenic mouse model of prostate cancer known as TRAMP. These data support the use of the TRAMP model to examine the molecular mechanisms involved in GTP-mediated prostate cancer chemoprevention. Recently, green tea polyphenols were identified as potent inhibitors of DNA methylation, a critical oncogenic mechanism. This suggests a novel and direct mechanism to account for the chemopreventive properties of GTP. Based on these data, it is hypothesized that DNA methylation changes are involved in the etiology of TRAMP prostate cancer, and that the chemopreventive effect of GTP in TRAMP is due to its ability to prevent or reverse aberrant DNA hypermethylation. To test this hypothesis, this proposal will: 1) Define the epigenetic changes coincident with prostate cancer progression in the TRAMP model; and 2) Determine the effect of GTP treatment on epigenetic parameters in TRAMP mice. Because prostate cancer has a long latency period and is most prevalent in men over the age of 65, dietary interventions that modestly delay progression time would have a profound impact on prostate cancer death rates. In this regard, GTP has the potential for significant utility as a chemopreventive agent in prostate cancer patients. Understanding the molecular mechanism(s) responsible for the activity of GTP is essential for the optimal design of prostate cancer chemoprevention trials and for the identification of novel molecular biomarkers to follow in clinical studies of GTP.
StatusFinished
Effective start/end date9/15/068/31/09

Funding

  • National Institutes of Health: $148,271.00
  • National Institutes of Health: $145,523.00

Fingerprint

Tea
Guanosine Triphosphate
Prostatic Neoplasms
DNA
Chemoprevention
DNA Methylation
Epigenomics
Polyphenols
Tumor Burden
Transgenic Mice
Epidemiologic Studies
Biomarkers
Neoplasm Metastasis
Mortality

ASJC

  • Medicine(all)